Core Viewpoint - The article discusses the evolution and future prospects of China's medical investment landscape over the next decade, highlighting significant changes and opportunities in the industry, particularly in innovative pharmaceuticals and medical technology [2][3]. Summary by Sections Historical Context - The period from 2015 to 2024 marks a complete decade of development for China's innovative drug sector, with a focus on both achievements and future directions for medical investment [3]. Key Milestones in 2025 - 2025 is identified as a historic year for the medical industry, with notable events such as the emergence of Eli Lilly as the first trillion-dollar company in the healthcare sector, reflecting the industry's potential for high market valuations [4]. - The Hong Kong Stock Exchange has become a crucial platform for medical companies, achieving a financing amount of $36 billion and nearly 100 listed companies, with 10% being healthcare firms, particularly in innovative drugs [4]. - Significant business development (BD) transactions have occurred, including a landmark $1.25 billion upfront payment to 3SBio, indicating growing international recognition of Chinese innovative drug intellectual property [4]. Industry Growth and Changes - The past decade has seen a dramatic increase in clinical trial institutions from 400 to approximately 1,600, and the number of personnel in China's drug review center has risen from 100 to nearly 700, although still lagging behind the U.S. [6]. - The shift from licensing in to licensing out has transformed China's role in the global pharmaceutical market, with the country becoming the largest marketplace for innovative drugs [6][7]. Future Predictions - The article predicts that during the 14th Five-Year Plan, China will solidify its position as the world's largest innovative drug marketplace and will strive to achieve parity with the U.S. in original innovation [8]. - The integration of AI in healthcare is expected to grow significantly, with applications in clinical settings and drug development, indicating a trend towards more advanced healthcare solutions [9][11]. Investment Themes - Four core investment themes for the next decade are identified: 1. Original innovation in pharmaceuticals will be a key investment direction, potentially yielding high returns [10]. 2. The evolution of the Hong Kong Stock Exchange and the STAR Market will facilitate investment in innovative companies lacking immediate revenue or profits [10]. 3. The combination of AI and healthcare will lead to more practical applications, including AI-driven pharmaceuticals and home healthcare robots [11]. 4. As Chinese pharmaceutical innovation and international expansion continue, the market capitalization of leading companies may exceed one trillion, with the emergence of global multinational corporations [11].